At a Glance
- Companies: Takeda, Sonoma Biotherapeutics, Vedanta, Merck KGaA/EMD Serono, others
- Location: US-focused
- Headline figures: 9 companies; ~243 at Takeda alone
- Focus area: Pipeline reprioritisation, patent cliffs
- Next steps: Resource shift to priority programmes
What happened?
At least nine biopharma companies announced workforce reductions in the first weeks of 2026, continuing a trend from 2025 when cuts rose 16%. Notable examples include Takeda’s layoff of 243 US field-based neuroscience employees ahead of Trintellix patent expiry and Sonoma Biotherapeutics’ broad cuts to extend runway.
Why does it matter?
Ongoing pressures from patent cliffs, clinical failures and funding squeezes force reprioritisation, despite hopes for 2026 stabilisation. Layoffs free capital for high-potential assets but signal sector caution amid biotech funding drought and big pharma efficiency drives.
Who’s behind it?
Takeda shifts from neuroscience sales to new launches; Sonoma (regulatory T-cell therapy) trims across functions for phase 1 RA focus. Others: Vedanta Biosciences (Jan 16), Merck KGaA’s EMD Serono (Jan 13).
How was it achieved?
Companies cite strategic realignment: Takeda navigates Trintellix loss (Dec 2026) via redeployment offers; Sonoma “right-sizes” for cash into 2027/28. Layoffs span field, R&D and support roles, often per WARN notices.
What’s next?
Firms extend runways (e.g., Sonoma to 2027+), advance key trials and hire selectively for launches. Broader sector watches for M&A acceleration.
What are people saying?
Sonoma: “Align resources with highest priorities.” EY: 2026 “more favourable” than 2025 despite early cuts. Takeda: “Reprioritizing for new US launches.”